Urinary adenosine excretion in type 1 diabetes - PubMed (original) (raw)
. 2017 Aug 1;313(2):F184-F191.
doi: 10.1152/ajprenal.00043.2017. Epub 2017 Apr 5.
Yuliya Lytvyn 1 3, Andrea Bozovic 4, Julie A Lovshin 1 5, Eleftherios Diamandis 4, Daniel Cattran 1, Mansoor Husain 6, Bruce A Perkins 5, Andrew Advani 7, Heather N Reich 1, Vathany Kulasingam 4, David Z I Cherney 8 2
Affiliations
- PMID: 28381459
- DOI: 10.1152/ajprenal.00043.2017
Free article
Urinary adenosine excretion in type 1 diabetes
Harindra Rajasekeran et al. Am J Physiol Renal Physiol. 2017.
Free article
Abstract
In experimental models of diabetes, augmented sodium-glucose cotransport-2 (SGLT2) activity diminishes sodium (Na+) delivery at the macula densa. As a result, less vasoconstrictive adenosine is generated, leading to afferent arteriolar vasodilatation and hyperfiltration. The measurement and significance of urinary adenosine in humans has not been examined extensively in states of renal hemodynamic impairment like that of diabetes. Our aim was to validate a method for urine adenosine quantification in humans and perform an exploratory post hoc analysis to determine whether urinary adenosine levels change dynamically in response to natriuresis in patients with type 1 diabetes (T1D) before and after treatment with the SGLT2 inhibitor (SGLT2i) empagliflozin. We hypothesized that SGLT2i, which reduces renal hyperfiltration through increased Na+ delivery to the macula densa, would increase urinary adenosine excretion. Urine adenosine corrected for creatinine was measured using our validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method in 40 healthy participants and 40 patients with T1D. In the T1D cohort, measurements were performed during clamped euglycemic and hyperglycemic conditions before and following 8 wk of SGLT2i therapy. Urinary adenosine was detectable in healthy subjects (0.32 ± 0.11 µmol/mmol Cr) and patients with T1D. In response to SGLT2i, urine adenosine increased during clamped hyperglycemia (0.40 ± 0.11 vs. 0.45 ± 0.12 µmol/mmol Cr, P = 0.005). Similar trends were observed during clamped euglycemia (P = 0.08). In conclusion, SGLT2i increases urinary adenosine excretion under clamped hyperglycemic conditions in patients with T1D. The potentially protective role of SGLT2i against glomerular hyperfiltration and its mediation by adenosine in diabetes merits further study.
Keywords: diabetic chronic kidney disease; liquid chromatography-tandem mass spectrometry; urinary adenosine.
Copyright © 2017 the American Physiological Society.
Similar articles
- Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Cherney DZ, et al. Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13. Circulation. 2014. PMID: 24334175 Clinical Trial. - Renal hyperfiltration is associated with glucose-dependent changes in fractional excretion of sodium in patients with uncomplicated type 1 diabetes.
Yang GK, Har RL, Lytvyn Y, Yip P, Cherney DZ. Yang GK, et al. Diabetes Care. 2014 Oct;37(10):2774-81. doi: 10.2337/dc14-0798. Epub 2014 Jul 10. Diabetes Care. 2014. PMID: 25011944 - Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus.
Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ. Lytvyn Y, et al. Am J Physiol Renal Physiol. 2015 Jan 15;308(2):F77-83. doi: 10.1152/ajprenal.00555.2014. Epub 2014 Nov 5. Am J Physiol Renal Physiol. 2015. PMID: 25377916 - Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE. Dailey GE. Drugs Today (Barc). 2015 Sep;51(9):519-35. doi: 10.1358/dot.2015.51.9.2368554. Drugs Today (Barc). 2015. PMID: 26488032 Review. - Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Škrtić M, Cherney DZ. Škrtić M, et al. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):96-103. doi: 10.1097/MNH.0000000000000084. Curr Opin Nephrol Hypertens. 2015. PMID: 25470017 Review.
Cited by
- Effects of Preanalytical Sample Collection and Handling on Comprehensive Metabolite Measurements in Human Urine Biospecimens.
Braisted J, Henderson T, Newman JW, Moore SC, Sampson J, McClain K, Ross S, Baer DJ, Mathé EA, Zanetti KA. Braisted J, et al. medRxiv [Preprint]. 2024 Jan 25:2024.01.24.24301735. doi: 10.1101/2024.01.24.24301735. medRxiv. 2024. PMID: 38410429 Free PMC article. Updated. Preprint. - Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.
Koh ES, Kim GH, Chung S. Koh ES, et al. Endocrinol Metab (Seoul). 2023 Aug;38(4):359-372. doi: 10.3803/EnM.2023.1764. Epub 2023 Jul 24. Endocrinol Metab (Seoul). 2023. PMID: 37482684 Free PMC article. Review. - Development of Optical-Based Molecularly Imprinted Nanosensors for Adenosine Detection.
Kurt ZT, Çimen D, Denizli A, Bereli N. Kurt ZT, et al. ACS Omega. 2023 May 18;8(21):18839-18850. doi: 10.1021/acsomega.3c01028. eCollection 2023 May 30. ACS Omega. 2023. PMID: 37273602 Free PMC article. - Emerging Role of Sodium-Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease.
Isidto R, Danguilan R, Naidas O, Vilanueva R, Arakama MH, Paraiso LM. Isidto R, et al. Int J Nephrol Renovasc Dis. 2023 Feb 21;16:43-57. doi: 10.2147/IJNRD.S387262. eCollection 2023. Int J Nephrol Renovasc Dis. 2023. PMID: 36852177 Free PMC article. Review. - Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system.
Chen X, Delić D, Cao Y, Shen L, Shao Q, Zhang Z, Wu H, Hasan AA, Reichetzeder C, Gaballa MMS, Krämer BK, Klein T, Yin L, He B, Morgera S, Hocher B. Chen X, et al. Am J Physiol Cell Physiol. 2023 Apr 1;324(4):C951-C962. doi: 10.1152/ajpcell.00528.2022. Epub 2023 Feb 13. Am J Physiol Cell Physiol. 2023. PMID: 36779666 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials